$BCYC
Bicycle Therapeutics PLC

2024 Q2 Form 10-Q Financial Statement

#000155837024010949 Filed on August 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q2
Revenue $9.361M
YoY Change -17.86%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.05M
YoY Change 5.75%
% of Gross Profit
Research & Development $40.06M
YoY Change 0.85%
% of Gross Profit
Depreciation & Amortization $1.600M
YoY Change -2.74%
% of Gross Profit
Operating Expenses $56.01M
YoY Change 2.02%
Operating Profit -$46.65M
YoY Change 8.2%
Interest Expense $7.051M
YoY Change 1750.66%
% of Operating Profit
Other Income/Expense, Net $6.950M
YoY Change -77322.22%
Pretax Income -$39.70M
YoY Change -7.94%
Income Tax $100.0K
% Of Pretax Income
Net Earnings -$39.80M
YoY Change -6.58%
Net Earnings / Revenue -425.17%
Basic Earnings Per Share -$0.77
Diluted Earnings Per Share -$0.77
COMMON SHARES
Basic Shares Outstanding 51.99M
Diluted Shares Outstanding 51.99M

Balance Sheet

Concept 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $961.4M
YoY Change 182.39%
Cash & Equivalents $961.4M
Short-Term Investments
Other Short-Term Assets $20.22M
YoY Change 101.7%
Inventory
Prepaid Expenses
Receivables $233.0K
Other Receivables $46.44M
Total Short-Term Assets $1.028B
YoY Change 151.76%
LONG-TERM ASSETS
Property, Plant & Equipment $11.59M
YoY Change -65.51%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.579M
YoY Change -45.83%
Total Long-Term Assets $29.10M
YoY Change -36.38%
TOTAL ASSETS
Total Short-Term Assets $1.028B
Total Long-Term Assets $29.10M
Total Assets $1.057B
YoY Change 132.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.453M
YoY Change 41.96%
Accrued Expenses $28.14M
YoY Change -18.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $22.40M
YoY Change
Total Short-Term Liabilities $69.61M
YoY Change -3.67%
LONG-TERM LIABILITIES
Long-Term Debt $8.505M
YoY Change -72.13%
Other Long-Term Liabilities $4.702M
YoY Change -96.42%
Total Long-Term Liabilities $13.21M
YoY Change -91.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $69.61M
Total Long-Term Liabilities $13.21M
Total Liabilities $183.5M
YoY Change -21.59%
SHAREHOLDERS EQUITY
Retained Earnings -$578.1M
YoY Change 40.04%
Common Stock $889.0K
YoY Change 124.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $873.8M
YoY Change
Total Liabilities & Shareholders Equity $1.057B
YoY Change 132.81%

Cashflow Statement

Concept 2024 Q2
OPERATING ACTIVITIES
Net Income -$39.80M
YoY Change -6.58%
Depreciation, Depletion And Amortization $1.600M
YoY Change -2.74%
Cash From Operating Activities -$44.63M
YoY Change -230.89%
INVESTING ACTIVITIES
Capital Expenditures $420.0K
YoY Change 51.62%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$420.0K
YoY Change 51.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 549.6M
YoY Change 4371.25%
NET CHANGE
Cash From Operating Activities -44.63M
Cash From Investing Activities -420.0K
Cash From Financing Activities 549.6M
Net Change In Cash 504.6M
YoY Change 994.23%
FREE CASH FLOW
Cash From Operating Activities -$44.63M
Capital Expenditures $420.0K
Free Cash Flow -$45.05M
YoY Change -233.2%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
dei Entity Central Index Key
EntityCentralIndexKey
0001761612
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2024Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2024Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38916
dei Entity Registrant Name
EntityRegistrantName
Bicycle Therapeutics plc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
dei Entity Address Address Line1
EntityAddressAddressLine1
Blocks A & B, Portway Building, Granta Park
dei Entity Address City Or Town
EntityAddressCityOrTown
Great Abington, Cambridge,
dei Entity Address Country
EntityAddressCountry
GB
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
CB21 6GS
dei City Area Code
CityAreaCode
+44
dei Local Phone Number
LocalPhoneNumber
1223 261503
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
961364000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
526423000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
233000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
20216000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11406000
CY2024Q2 bcyc Research And Development Incentives Receivable Current
ResearchAndDevelopmentIncentivesReceivableCurrent
46443000
CY2023Q4 bcyc Research And Development Incentives Receivable Current
ResearchAndDevelopmentIncentivesReceivableCurrent
24039000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
1028256000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
561868000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11587000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14515000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10933000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13169000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6579000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5792000
CY2024Q2 us-gaap Assets
Assets
1057355000
CY2023Q4 us-gaap Assets
Assets
595344000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
7453000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13050000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28135000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31509000
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
11619000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
24978000
CY2024Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
22404000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
69611000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
69537000
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8505000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
30698000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6730000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9382000
CY2024Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
93994000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
110216000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4702000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4579000
CY2024Q2 us-gaap Liabilities
Liabilities
183542000
CY2023Q4 us-gaap Liabilities
Liabilities
224412000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
154385145
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
59612613
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68941242
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68941242
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42431766
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42431766
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
889000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
550000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1452151000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
883446000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1092000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1304000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-578135000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-511760000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
873813000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
370932000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1057355000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
595344000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9361000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11397000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28891000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16293000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40059000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39720000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
74923000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
71931000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15949000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14788000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32331000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29276000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
56008000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
54508000
us-gaap Operating Expenses
OperatingExpenses
107254000
us-gaap Operating Expenses
OperatingExpenses
101207000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-46647000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-43111000
us-gaap Operating Income Loss
OperatingIncomeLoss
-78363000
us-gaap Operating Income Loss
OperatingIncomeLoss
-84914000
CY2024Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
7774000
CY2023Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
812000
us-gaap Interest And Other Income
InterestAndOtherIncome
13398000
us-gaap Interest And Other Income
InterestAndOtherIncome
3741000
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
824000
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
821000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1645000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1629000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6950000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11753000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2112000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39697000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43120000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-66610000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-82802000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
115000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-517000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-235000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1135000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-39812000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-42603000
us-gaap Net Income Loss
NetIncomeLoss
-66375000
us-gaap Net Income Loss
NetIncomeLoss
-81667000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.77
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.77
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.41
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.71
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51992034
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51992034
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30191693
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30191693
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47276062
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47276062
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30097234
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30097234
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-39812000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-42603000
us-gaap Net Income Loss
NetIncomeLoss
-66375000
us-gaap Net Income Loss
NetIncomeLoss
-81667000
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-314000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-948000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
212000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1264000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40126000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43551000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66163000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-82931000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
370932000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1870000
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9282000
CY2024Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
526000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-26563000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
356048000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4500000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
11400000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
544127000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9264000
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-314000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-39812000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
873813000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
270783000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
100000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2716000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9042000
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-316000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-39064000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
243163000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
165000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
400000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12127000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8193000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-948000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-42603000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
220097000
us-gaap Profit Loss
ProfitLoss
-66375000
us-gaap Profit Loss
ProfitLoss
-81667000
us-gaap Share Based Compensation
ShareBasedCompensation
18546000
us-gaap Share Based Compensation
ShareBasedCompensation
17235000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3298000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3202000
bcyc Non Cash Interest Expense
NonCashInterestExpense
211000
bcyc Non Cash Interest Expense
NonCashInterestExpense
198000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-877000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-3683000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
232000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-52358000
bcyc Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
22575000
bcyc Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
-7199000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8783000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
638000
bcyc Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-2187000
bcyc Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-2054000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6354000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
21000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3626000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
8416000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2382000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1867000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-28671000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-15454000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
137000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
311000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-115496000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12315000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
432000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2376000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-432000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2376000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
545106000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14843000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6371000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
167000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
551477000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15010000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-608000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
960000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
434941000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1279000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
526970000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
339154000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
961911000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
340433000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
961364000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
340433000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
547000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
961911000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
340433000
us-gaap Interest Paid Net
InterestPaidNet
1146000
us-gaap Interest Paid Net
InterestPaidNet
1365000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
792000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
664000
bcyc Equity Issuance Costs Included In Accounts Payable And Accrued
EquityIssuanceCostsIncludedInAccountsPayableAndAccrued
979000
us-gaap Operating Lease Payments
OperatingLeasePayments
2874000
us-gaap Operating Lease Payments
OperatingLeasePayments
2771000
bcyc Increase Decrease Capital Expenditures Incurred But Not Yet Paid
IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid
26000
bcyc Increase Decrease Capital Expenditures Incurred But Not Yet Paid
IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid
-1401000
bcyc Advance Billings On Deferred Revenue Included In Accounts Receivable
AdvanceBillingsOnDeferredRevenueIncludedInAccountsReceivable
45000000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4004000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
961400000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-39800000
us-gaap Net Income Loss
NetIncomeLoss
-66400000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-42600000
us-gaap Net Income Loss
NetIncomeLoss
-81700000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-578100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of estimates </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the accrual for research and development expenses and research and development incentives receivable, share-based compensation expense, valuation of right-of-use assets and liabilities and income taxes, including the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of reasonable changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.</p>
CY2024Q2 bcyc Reduction Of Research And Development Expense
ReductionOfResearchAndDevelopmentExpense
7300000
bcyc Reduction Of Research And Development Expense
ReductionOfResearchAndDevelopmentExpense
22600000
CY2023Q2 bcyc Reduction Of Research And Development Expense
ReductionOfResearchAndDevelopmentExpense
5700000
bcyc Reduction Of Research And Development Expense
ReductionOfResearchAndDevelopmentExpense
12600000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
500000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
28193000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
27908000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16606000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13393000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11587000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14515000
CY2024Q2 us-gaap Depreciation
Depreciation
1600000
us-gaap Depreciation
Depreciation
3300000
CY2023Q2 us-gaap Depreciation
Depreciation
1600000
us-gaap Depreciation
Depreciation
3200000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9237000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13394000
CY2024Q2 bcyc Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
11714000
CY2023Q4 bcyc Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
11839000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1437000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1143000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5098000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4876000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
649000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
257000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28135000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31509000
CY2020Q3 us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.0455
CY2024Q2 bcyc Debt Instrument Prepayment Option Excess Of Outstanding Amount
DebtInstrumentPrepaymentOptionExcessOfOutstandingAmount
5000000.0
CY2024Q2 bcyc Debt Instrument End Of Term Charge Rate
DebtInstrumentEndOfTermChargeRate
0.050
CY2024Q2 bcyc Debt Instrument Additional Interest Rate Event Of Default
DebtInstrumentAdditionalInterestRateEventOfDefault
0.050
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2024Q2 bcyc Debt End Of Term Charge
DebtEndOfTermCharge
1092000
CY2023Q4 bcyc Debt End Of Term Charge
DebtEndOfTermCharge
946000
CY2024Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
183000
CY2023Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
248000
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
30909000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
30698000
CY2024Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
22404000
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8505000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
30698000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
31500000
CY2024Q2 bcyc Long Term Debt Including End Term Charge
LongTermDebtIncludingEndTermCharge
31500000
bcyc Number Of Vote Per Share
NumberOfVotePerShare
1
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2023 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
154385145
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
59612613
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9264000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8193000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18546000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17235000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9361000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11397000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28891000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16293000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
135194000
bcyc Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
233000
bcyc Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
28891000
bcyc Contract With Customer Liability Foreign Currency Adjustment
ContractWithCustomerLiabilityForeignCurrencyAdjustment
923000
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
105613000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
61873000
CY2023 bcyc Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
95960000
CY2023 bcyc Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
26976000
CY2023 bcyc Contract With Customer Liability Foreign Currency Adjustment
ContractWithCustomerLiabilityForeignCurrencyAdjustment
-4337000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
135194000
CY2024Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0
CY2024Q2 bcyc Contract With Customer Liability Revenue Recognized Proportional Performance Obligation
ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation
6819000
CY2023Q2 bcyc Contract With Customer Liability Revenue Recognized Proportional Performance Obligation
ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation
3927000
bcyc Contract With Customer Liability Revenue Recognized Proportional Performance Obligation
ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation
18450000
bcyc Contract With Customer Liability Revenue Recognized Proportional Performance Obligation
ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation
8823000
CY2024Q2 bcyc Contract With Customer Liability Revenue Recognized Expiration Of Material Rights
ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights
2542000
CY2023Q2 bcyc Contract With Customer Liability Revenue Recognized Expiration Of Material Rights
ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights
7470000
bcyc Contract With Customer Liability Revenue Recognized Expiration Of Material Rights
ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights
10576000
bcyc Contract With Customer Liability Revenue Recognized Expiration Of Material Rights
ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights
7470000
bcyc Contract With Customer Liability Revenue Recognized Changes In Transaction Price
ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice
-135000
CY2024Q2 bcyc Total Revenue Recognized From Both Beginning Balance And Current Period Increase In Contract Liability
TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability
9361000
CY2023Q2 bcyc Total Revenue Recognized From Both Beginning Balance And Current Period Increase In Contract Liability
TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability
11397000
bcyc Total Revenue Recognized From Both Beginning Balance And Current Period Increase In Contract Liability
TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability
28891000
bcyc Total Revenue Recognized From Both Beginning Balance And Current Period Increase In Contract Liability
TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability
16293000
CY2016Q4 bcyc Research And Development Arrangement Obligation To Repay Other Parties
ResearchAndDevelopmentArrangementObligationToRepayOtherParties
50900000
CY2019Q4 bcyc Research And Development Arrangement Obligation To Repay Other Parties
ResearchAndDevelopmentArrangementObligationToRepayOtherParties
60300000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-200000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-500000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1100000
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1338000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1367000
us-gaap Operating Lease Cost
OperatingLeaseCost
2679000
us-gaap Operating Lease Cost
OperatingLeaseCost
2693000
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
563000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
803000
us-gaap Variable Lease Cost
VariableLeaseCost
1344000
us-gaap Variable Lease Cost
VariableLeaseCost
1451000
CY2024Q2 us-gaap Lease Cost
LeaseCost
1901000
CY2023Q2 us-gaap Lease Cost
LeaseCost
2170000
us-gaap Lease Cost
LeaseCost
4023000
us-gaap Lease Cost
LeaseCost
4144000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y4M24D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.079
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.076
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2878000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5839000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3340000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
821000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1050000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
11828000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5098000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6730000
bcyc Maximum Days Allowed For Cancellation Of Contracts Prior Written Notice
MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice
P90D
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-39812000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42603000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-66375000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-81667000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51992034
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51992034
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30191693
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30191693
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47276062
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47276062
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30097234
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30097234
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.77
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.77
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.41
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.71
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9664509
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7709897
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2024Q2 us-gaap Noncurrent Assets
NoncurrentAssets
22520000
CY2023Q4 us-gaap Noncurrent Assets
NoncurrentAssets
27684000
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-010949-index-headers.html Edgar Link pending
0001558370-24-010949-index.html Edgar Link pending
0001558370-24-010949.txt Edgar Link pending
0001558370-24-010949-xbrl.zip Edgar Link pending
bcyc-20240630.xsd Edgar Link pending
bcyc-20240630x10q.htm Edgar Link pending
bcyc-20240630xex10d4.htm Edgar Link pending
bcyc-20240630xex10d4001.jpg Edgar Link pending
bcyc-20240630xex31d1.htm Edgar Link pending
bcyc-20240630xex31d2.htm Edgar Link pending
bcyc-20240630xex32d1.htm Edgar Link pending
bcyc-20240630xex3d1.htm Edgar Link pending
bcyc-20240630_cal.xml Edgar Link unprocessable
bcyc-20240630_def.xml Edgar Link unprocessable
bcyc-20240630_lab.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bcyc-20240630x10q_htm.xml Edgar Link completed
bcyc-20240630_pre.xml Edgar Link unprocessable